The rate of FGF19 baseline in the objective response (OR) and non-OR groups was 2.09 vs. 1.32 at four weeks and 2.19 vs. 1.40 at eight weeks, respectively, showing the clinical response predictive value of circulating FGF19 in early HCC patients [108]. The gene discussed is FGF19; the disease is hepatocellular carcinoma.